---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-023703"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:37:37.854745+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences terminates HQ lease, separates CEO, CFO, and COO ahead of Aurinia merger

## Summary
- Lease for ~48,714 sq ft at 4000 Shoreline Court terminated April 1; company pays $2M ( $1.3M cash + $0.7M security deposit).
- CEO Christopher Kirk, CFO Marc Belsky, and COO Mark Schiller enter separation agreements; employment ends at merger close or earlier.
- Kirk receives lump-sum severance of 18 months base salary plus pro-rata bonus; Belsky and Schiller get 12 months COBRA cash payment.
- No disagreements between officers and company; severance contingent on signing general release.
- Merger with Aurinia Pharma U.S. at $6.955/share plus CVR still expected to close.

## SEC filing metadata
- accession: 0001628280-26-023703
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000162828026023703/0001628280-26-023703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000162828026023703/kzr-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-023703
- JSON: https://secwatch.observer/filing/0001628280-26-023703.json
- Plain text: https://secwatch.observer/filing/0001628280-26-023703.txt

## Source-grounded claims
- claim_id: c6d1d352bfcc555c29897fda2e0573b46d47ac0a
  claim: Kezar Life Sciences, Inc. terminated Lease Termination Agreement with GNS South Tower, LP valued at $2 million (effective 2026-04-01).
  evidence_excerpt: On April 1, 2026, Kezar Life Sciences, Inc. (the “Company”) entered into a lease termination agreement (the “Lease Termination Agreement”) with GNS South Tower, LP (the “Landlord”) to terminate that certain lease agreement, dated as of August 16, 2017, as amended (the “Lease”), for approximately 48,714 rentable square feet at 4000 Shoreline Court, San Francisco, California.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000162828026023703/0001628280-26-023703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.